NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1

Updated: Feb 4

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma

iMMagine-1

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma

A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy.

Sponsor

Collaborator

ClinicalTrials.gov Identifier: NCT05396885

Official Title: A Phase II Study of CART-ddBMCA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (iMMagine-1)

First Posted: May 31, 2022

Click here to see details on ClinicalTrials.gov

Biological: CART-ddBCMA

BCMA-directed CAR T-cell therapy using d domain

Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA (Code C167337)

Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA

Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein

ARC-T Plus Anti-BCMA SparX

Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA

TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells

Locations

United States, Massachusetts

Massachusetts General Hospital

United States, Wisconsin

Medical College of Wisconsin